Drs. Huizinga, Toes, and Ioan-Facsinay have a patent application pending for the use of the peptide sequences in tolerization protocols.
Rheumatoid Arthritis Basic Science Studies
Identification of citrullinated vimentin peptides as T cell epitopes in HLA–DR4–positive patients with rheumatoid arthritis
Version of Record online: 28 DEC 2009
Copyright © 2010 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 62, Issue 1, pages 117–125, January 2010
How to Cite
Feitsma, A. L., van der Voort, E. I. H., Franken, K. L. M. C., El Bannoudi, H., Elferink, B. G., Drijfhout, J. W., Huizinga, T. W. J., de Vries, R. R. P., Toes, R. E. M. and Ioan-Facsinay, A. (2010), Identification of citrullinated vimentin peptides as T cell epitopes in HLA–DR4–positive patients with rheumatoid arthritis. Arthritis & Rheumatism, 62: 117–125. doi: 10.1002/art.25059
- Issue online: 28 DEC 2009
- Version of Record online: 28 DEC 2009
- Manuscript Accepted: 25 SEP 2009
- Manuscript Received: 29 APR 2009
- European Commission Sixth Framework Programme Autocure and European Commission Seventh Framework Programme Masterswitch
- Dutch Organization for Scientific Research (VIDI). Grant Number: VENI grant 916.46.079
- 11The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006; 54: 1117–21., , , , , .
- 25Definition of MHC and T cell receptor contacts in the HLA-DR4 restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc Natl Acad Sci U S A 1998; 95: 7574–9., , , , , , et al.
- 28Distinct HLA-DR epitopes and distinct families of HLA-Dr molecules defined by 15 monoclonal antibodies (mAb) either anti-DR or allo-anti-Iak cross-reacting with human DR molecule. I. Cross-inhibition studies of mAb cell surface fixation and differential binding of mAb to detergent-solubilized HLA molecules immobilized to a solid phase by a first mAb. Eur J Immunol 1983; 13: 106–11., , , , , .